Home Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy
Article
Licensed
Unlicensed Requires Authentication

Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy

  • Jong Hyun Jhee , Hye-Young Kang , Meiyan Wu , Bo Young Nam , Tae-Ik Chang , Su-Young Jung , Seohyun Park , Hyoungnae Kim , Hae-Ryong Yun , Youn Kyung Kee , Chang-Yun Yoon , Jung Tak Park , Tae-Hyun Yoo , Shin-Wook Kang and Seung Hyeok Han EMAIL logo
Published/Copyright: June 16, 2017
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 56 Issue 1

Abstract

Background:

Soluble CD89 (sCD89)-IgA complex plays a key role in the pathogenesis of IgA nephropathy (IgAN). However, there is a lack of evidence supporting this complex as a good biomarker for disease progression. This study aimed to evaluate the usefulness of sCD89-IgA complex for risk stratification of IgAN.

Methods:

A total of 326 patients with biopsy-proven IgAN were included. sCD89-IgA complex was measured by sandwich-enzyme-linked immunosorbent assay. The study endpoints were a 30% decline in estimated glomerular filtration rate (eGFR).

Results:

sCD89-IgA complex levels were inversely and weakly associated with eGFR at the time of biopsy (r=−0.12, p=0.03). However, the significance between the two factors was lost in the multivariate linear regression after adjustment of clinical factors (β=0.35, p=0.75). In a multivariate Cox model, the highest (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.35–1.61; p=0.45) and middle (HR, 0.93; 95% CI, 0.46–1.89; p=0.84) tertiles of sCD89-IgA complex levels were not associated with an increased risk of developing a 30% decrease in eGFR. Furthermore, the decline rates in eGFR did not differ between groups and C-statistics revealed that the sCD89-IgA complex were not superior to clinical factors in predicting disease progression.

Conclusions:

This study found no association between sCD89-IgA complex levels and disease progression in IgAN. Although sCD89 can contribute to the formation of immune complexes, our findings suggest that the sCD89-IgA level is not a good predictor of adverse outcomes and has limited clinical utility as a biomarker for risk stratification in IgAN.

Keywords: CD89; estimated glomerular filtration rate (eGFR); IgA nephropathy
Corresponding author: Seung Hyeok Han, MD, PhD, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea, Phone: 82-2-2228-1984, Fax: 82-2-393-6884
aJong Hyun Jhee and Hye-Young Kang contributed equally to this work.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Financial support: This study was supported by a faculty research grant of Yonsei University College of Medicine for 2015; Dr. Wu M is supported by China Scholarship Council.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med 2013;368:2402–14.10.1056/NEJMra1206793Search in Google Scholar

2. Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med 1990;89:209–15.10.1016/0002-9343(90)90300-3Search in Google Scholar

3. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002;347:738–48.10.1056/NEJMra020109Search in Google Scholar PubMed

4. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol 2005;16:2088–97.10.1681/ASN.2005020134Search in Google Scholar PubMed

5. McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 2011;26:414–30.10.1093/ndt/gfq665Search in Google Scholar PubMed

6. Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines – application to the individual patient. Kidney Int 2012;82:840–56.10.1038/ki.2012.280Search in Google Scholar PubMed

7. Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015;373:2225–36.10.1056/NEJMoa1415463Search in Google Scholar PubMed

8. Berthelot L, Papista C, Maciel TT, Biarnes-Pelicot M, Tissandie E, Wang PH, et al. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J Exp Med 2012;209:793–806.10.1084/jem.20112005Search in Google Scholar PubMed PubMed Central

9. Moura IC, Arcos-Fajardo M, Gdoura A, Leroy V, Sadaka C, Mahlaoui N, et al. Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J Am Soc Nephrol 2005;16:2667–76.10.1681/ASN.2004111006Search in Google Scholar PubMed

10. Floege J. The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches? Am J Kidney Dis 2011;58:992–1004.10.1053/j.ajkd.2011.05.033Search in Google Scholar PubMed

11. Mestecky J, Tomana M, Moldoveanu Z, Julian BA, Suzuki H, Matousovic K, et al. Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy. Kidney Blood Press Res 2008;31:29–37.10.1159/000112922Search in Google Scholar PubMed PubMed Central

12. Tanaka M, Seki G, Someya T, Nagata M, Fujita T. Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy. Clin Dev Immunol 2011;2011:470803.10.1155/2011/470803Search in Google Scholar PubMed PubMed Central

13. Ding JX, Xu LX, Lv JC, Zhao MH, Zhang H, Wang HY. Aberrant sialylation of serum IgA1 was associated with prognosis of patients with IgA nephropathy. Clin Immunol 2007;125:268–74.10.1016/j.clim.2007.08.009Search in Google Scholar PubMed

14. Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009;119:1668–77.10.1172/JCI38468Search in Google Scholar PubMed PubMed Central

15. Haddad E, Moura IC, Arcos-Fajardo M, Macher MA, Baudouin V, Alberti C, et al. Enhanced expression of the CD71 mesangial IgA1 receptor in Berger disease and Henoch-Schonlein nephritis: association between CD71 expression and IgA deposits. J Am Soc Nephrol 2003;14:327–37.10.1097/01.ASN.0000046961.04917.83Search in Google Scholar

16. Moura IC, Centelles MN, Arcos-Fajardo M, Malheiros DM, Collawn JF, Cooper MD, et al. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 2001;194:417–25.10.1084/jem.194.4.417Search in Google Scholar PubMed PubMed Central

17. Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 2001;167:2861–8.10.4049/jimmunol.167.5.2861Search in Google Scholar PubMed

18. Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006;17:1724–34.10.1681/ASN.2005090923Search in Google Scholar PubMed

19. Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 2008;19: 12–23.10.1681/ASN.2007050532Search in Google Scholar PubMed

20. Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010;6:643–56.10.1038/nrneph.2010.120Search in Google Scholar PubMed

21. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010;21:1819–34.10.1681/ASN.2010080793Search in Google Scholar PubMed

22. Ichii O, Otsuka S, Sasaki N, Yabuki A, Ohta H, Takiguchi M, et al. Local overexpression of interleukin-1 family, member 6 relates to the development of tubulointerstitial lesions. Lab Invest 2010;90:459–75.10.1038/labinvest.2009.148Search in Google Scholar PubMed

23. van der Boog PJ, De Fijter JW, Van Kooten C, Van Der Holst R, Van Seggelen A, Van Es LA, et al. Complexes of IgA with FcalphaRI/CD89 are not specific for primary IgA nephropathy. Kidney Int 2003;63:514–21.10.1046/j.1523-1755.2003.00756.xSearch in Google Scholar PubMed

24. Maliszewski CR, March CJ, Schoenborn MA, Gimpel S, Shen L. Expression cloning of a human Fc receptor for IgA. J Exp Med 1990;172:1665–72.10.1084/jem.172.6.1665Search in Google Scholar PubMed PubMed Central

25. Mostov KE. Transepithelial transport of immunoglobulins. Annu Rev Immunol 1994;12:63–84.10.1146/annurev.iy.12.040194.000431Search in Google Scholar PubMed

26. Yanagihara T, Kumagai Y, Norose Y, Moro I, Nanno M, Murakami M, et al. Age-dependent decrease of polymeric Ig receptor expression and IgA elevation in ddY mice: a possible cause of IgA nephropathy. Lab Invest 2004;84:63–70.10.1038/labinvest.3700012Search in Google Scholar PubMed

27. Inoue T, Sugiyama H, Hiki Y, Takiue K, Morinaga H, Kitagawa M, et al. Differential expression of glycogenes in tonsillar B lymphocytes in association with proteinuria and renal dysfunction in IgA nephropathy. Clin Immunol 2010;136:447–55.10.1016/j.clim.2010.05.009Search in Google Scholar PubMed

28. Stockert RJ, Kressner MS, Collins JC, Sternlieb I, Morell AG. IgA interaction with the asialoglycoprotein receptor. Proc Natl Acad Sci U S A 1982;79:6229–31.10.1073/pnas.79.20.6229Search in Google Scholar PubMed PubMed Central

29. Hahn-Zoric M, Vuong M, Lundberg S, Wramner L, Ahlmen J, Hanson LÅ, et al. Su.82. evidence for genetic regulation of Fc alpha receptor (CD89) expression: study of soluble CD89 in plasma of IgA nephropathy patients and healthy controls. Clin Immunol 2008;127:S151.10.1016/j.clim.2008.03.433Search in Google Scholar

30. Monteiro RC, Van De Winkel JG. IgA Fc receptors. Annu Rev Immunol 2003;21:177–204.10.1146/annurev.immunol.21.120601.141011Search in Google Scholar PubMed

31. Vuong MT, Hahn-Zoric M, Lundberg S, Gunnarsson I, van Kooten C, Wramner L, et al. Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy. Kidney Int 2010;78:1281–7.10.1038/ki.2010.314Search in Google Scholar PubMed

32. Launay P, Grossetete B, Arcos-Fajardo M, Gaudin E, Torres SP, Beaudoin L, et al. Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger’s disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice. J Exp Med 2000;191:1999–2009.10.1084/jem.191.11.1999Search in Google Scholar PubMed PubMed Central

33. Berthelot L, Robert T, Vuiblet V, Tabary T, Braconnier A, Drame M, et al. Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes. Kidney Int 2015;88:815–22.10.1038/ki.2015.158Search in Google Scholar PubMed

34. Barbour SJ, Reich HN. Risk stratification of patients with IgA nephropathy. Am J Kidney Dis 2012;59:865–73.10.1053/j.ajkd.2012.02.326Search in Google Scholar PubMed

35. Geddes CC, Rauta V, Gronhagen-Riska C, Bartosik LP, Jardine AG, Ibels LS, et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant 2003;18:1541–8.10.1093/ndt/gfg207Search in Google Scholar PubMed

36. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–70.10.7326/0003-4819-130-6-199903160-00002Search in Google Scholar PubMed

37. van Zandbergen G, Westerhuis R, Mohamad NK, van De Winkel JG, Daha MR, van Kooten C. Crosslinking of the human Fc receptor for IgA (FcalphaRI/CD89) triggers FcR gamma-chain-dependent shedding of soluble CD89. J Immunol 1999;163:5806–12.10.4049/jimmunol.163.11.5806Search in Google Scholar

38. Grossetete B, Launay P, Lehuen A, Jungers P, Bach JF, Monteiro RC. Down-regulation of Fc alpha receptors on blood cells of IgA nephropathy patients: evidence for a negative regulatory role of serum IgA. Kidney Int 1998;53:1321–35.10.1046/j.1523-1755.1998.00885.xSearch in Google Scholar PubMed

39. Boyd JK, Barratt J. Immune complex formation in IgA nephropathy: CD89 a ‘saint’ or a ‘sinner’? Kidney Int 2010;78:1211–3.10.1038/ki.2010.365Search in Google Scholar PubMed

40. Morton HC, Brandtzaeg P. CD89: the human myeloid IgA Fc receptor. Arch Immunol Ther Exp (Warsz) 2001;49:217–29.Search in Google Scholar

41. Birmingham DJ, Irshaid F, Nagaraja HN, Zou X, Tsao BP, Wu H, et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 2010;19:1272–80.10.1177/0961203310371154Search in Google Scholar PubMed PubMed Central

42. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997;8:199–207.10.1681/ASN.V82199Search in Google Scholar PubMed

43. Tissandie E, Morelle W, Berthelot L, Vrtovsnik F, Daugas E, Walker F, et al. Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases. Kidney Int 2011;80:1352–63.10.1038/ki.2011.276Search in Google Scholar PubMed

44. van der Boog PJ, van Zandbergen G, de Fijter JW, Klar-Mohamad N, van Seggelen A, Brandtzaeg P, et al. Fc alpha RI/CD89 circulates in human serum covalently linked to IgA in a polymeric state. J Immunol 2002;168:1252–8.10.4049/jimmunol.168.3.1252Search in Google Scholar PubMed

45. Westerhuis R, Van Zandbergen G, Verhagen NA, Klar-Mohamad N, Daha MR, van Kooten C. Human mesangial cells in culture and in kidney sections fail to express Fc alpha receptor (CD89). J Am Soc Nephrol 1999;10:770–8.10.1681/ASN.V104770Search in Google Scholar PubMed

46. Leung JC, Tsang AW, Chan DT, Lai KN. Absence of CD89, polymeric immunoglobulin receptor, and asialoglycoprotein receptor on human mesangial cells. J Am Soc Nephrol 2000;11:241–9.10.1681/ASN.V112241Search in Google Scholar PubMed

47. Diven SC, Caflisch CR, Hammond DK, Weigel PH, Oka JA, Goldblum RM. IgA induced activation of human mesangial cells: independent of FcalphaR1 (CD 89). Kidney Int 1998;54:837–47.10.1046/j.1523-1755.1998.00054.xSearch in Google Scholar PubMed

48. Lechner SM, Abbad L, Boedec E, Papista C, Le Stang MB, Moal C, et al. IgA1 protease treatment reverses mesangial deposits and hematuria in a model of IgA nephropathy. J AM Soc Nephrol 2016;27:2622–9.10.1681/ASN.2015080856Search in Google Scholar PubMed PubMed Central

49. Moresco RN, Speeckaert MM, Zmonarski SC, Krajewska M, Komuda-Leszek E, Perkowska-Ptasinska A, et al. Urinary myeloid IgA Fc alpha receptor (CD89) and transglutaminase-2 as new biomarkers for active IgA nephropathy and henoch-Schonlein purpura nephritis. BBA Clin 2016;5:79–84.10.1016/j.bbacli.2016.02.002Search in Google Scholar PubMed PubMed Central

50. Barbour SJ, Cattran DC, Kim SJ, Levin A, Wald R, Hladunewich MA, et al. Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney Int 2013;84:1017–24.10.1038/ki.2013.210Search in Google Scholar PubMed

Supplemental Material:

The online version of this article (https://doi.org/10.1515/cclm-2017-0090) offers supplementary material, available to authorized users.

Received: 2017-1-31
Accepted: 2017-4-17
Published Online: 2017-6-16
Published in Print: 2017-11-27

©2018 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Method comparison – a practical approach based on error identification
  4. Review
  5. Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease
  6. Mini Reviews
  7. α-Defensin point-of-care test for diagnosis of prosthetic joint infections: neglected role of laboratory and clinical pathologists
  8. The diagnostic accuracy of biomarkers for diagnosis of primary biliary cholangitis (PBC) in anti-mitochondrial antibody (AMA)-negative PBC patients: a review of literature
  9. Opinion Paper
  10. New issues on measurement of B-type natriuretic peptides
  11. Genetics and Molecular Diagnostics
  12. The SEeMORE strategy: single-tube electrophoresis analysis-based genotyping to detect monogenic diseases rapidly and effectively from conception until birth
  13. General Clinical Chemistry and Laboratory Medicine
  14. Determination of serum calcium levels by 42Ca isotope dilution inductively coupled plasma mass spectrometry
  15. The effects of dry ice exposure on plasma pH and coagulation analyses
  16. Placental protein-13 (PP13) in combination with PAPP-A and free leptin index (fLI) in first trimester maternal serum screening for severe and early preeclampsia
  17. Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy
  18. Performance analysis of automated evaluation of Crithidia luciliae-based indirect immunofluorescence tests in a routine setting – strengths and weaknesses
  19. Performance of automated digital cell imaging analyzer Sysmex DI-60
  20. Reference Values and Biological Variations
  21. Determination of reference intervals for urinary steroid profiling using a newly validated GC-MS/MS method
  22. Reference intervals and longitudinal changes in copeptin and MR-proADM concentrations during pregnancy
  23. Definition of the upper reference limit of glycated albumin in blood donors from Italy
  24. Reference values of fecal calgranulin C (S100A12) in school aged children and adolescents
  25. Processing-independent proANP measurement for low concentrations in plasma: reference intervals and effect of body mass index and plasma glucose
  26. Cancer Diagnostics
  27. Cancer sniffer dogs: how can we translate this peculiarity in laboratory medicine? Results of a pilot study on gastrointestinal cancers
  28. Cardiovascular Diseases
  29. NGAL and MMP-9/NGAL as biomarkers of plaque vulnerability and targets of statins in patients with carotid atherosclerosis
  30. Analytical evaluation of the new Beckman Coulter Access high sensitivity cardiac troponin I immunoassay
  31. Infectious Diseases
  32. Analytical evaluation of the performances of Diazyme and BRAHMS procalcitonin applied to Roche Cobas in comparison with BRAHMS PCT-sensitive Kryptor
  33. Effects of procalcitonin testing on antibiotic use and clinical outcomes in patients with upper respiratory tract infections. An individual patient data meta-analysis
  34. Acknowledgment
  35. Letters to the Editor
  36. Handling the altered test results of hemolyzed samples. Recommendations of the Quality, Management, Safety and Evidence Committee (CCGSE) of the Spanish Association of Medical Biopathology and Laboratory Medicine (AEBM-ML)
  37. Reply to: Analytical evaluation of the performances of Diazyme and BRAHMS procalcitonin applied to Roche Cobas in comparison with BRAHMS PCT-sensitive Kryptor
  38. Excessive hypercortisolemia due to ectopic Cushing’s syndrome requiring extending the reportable range for plasma cortisol for management
  39. Heavy chain disease: our experience
  40. An abnormal elevation of serum CA72-4 due to taking colchicine
  41. Rivaroxaban non-responders: do plasma measurements have a place?
  42. Next generation sequencing and immuno-histochemistry profiling identify numerous biomarkers for personalized therapy of endometrioid endometrial carcinoma
  43. A multicenter effort to improve comparability of vitamin B6 assays in whole blood
  44. PR3-anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis
https://doi.org/10.1515/cclm-2017-0090
Keywords for this article
CD89; estimated glomerular filtration rate (eGFR); IgA nephropathy

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Method comparison – a practical approach based on error identification
  4. Review
  5. Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease
  6. Mini Reviews
  7. α-Defensin point-of-care test for diagnosis of prosthetic joint infections: neglected role of laboratory and clinical pathologists
  8. The diagnostic accuracy of biomarkers for diagnosis of primary biliary cholangitis (PBC) in anti-mitochondrial antibody (AMA)-negative PBC patients: a review of literature
  9. Opinion Paper
  10. New issues on measurement of B-type natriuretic peptides
  11. Genetics and Molecular Diagnostics
  12. The SEeMORE strategy: single-tube electrophoresis analysis-based genotyping to detect monogenic diseases rapidly and effectively from conception until birth
  13. General Clinical Chemistry and Laboratory Medicine
  14. Determination of serum calcium levels by 42Ca isotope dilution inductively coupled plasma mass spectrometry
  15. The effects of dry ice exposure on plasma pH and coagulation analyses
  16. Placental protein-13 (PP13) in combination with PAPP-A and free leptin index (fLI) in first trimester maternal serum screening for severe and early preeclampsia
  17. Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy
  18. Performance analysis of automated evaluation of Crithidia luciliae-based indirect immunofluorescence tests in a routine setting – strengths and weaknesses
  19. Performance of automated digital cell imaging analyzer Sysmex DI-60
  20. Reference Values and Biological Variations
  21. Determination of reference intervals for urinary steroid profiling using a newly validated GC-MS/MS method
  22. Reference intervals and longitudinal changes in copeptin and MR-proADM concentrations during pregnancy
  23. Definition of the upper reference limit of glycated albumin in blood donors from Italy
  24. Reference values of fecal calgranulin C (S100A12) in school aged children and adolescents
  25. Processing-independent proANP measurement for low concentrations in plasma: reference intervals and effect of body mass index and plasma glucose
  26. Cancer Diagnostics
  27. Cancer sniffer dogs: how can we translate this peculiarity in laboratory medicine? Results of a pilot study on gastrointestinal cancers
  28. Cardiovascular Diseases
  29. NGAL and MMP-9/NGAL as biomarkers of plaque vulnerability and targets of statins in patients with carotid atherosclerosis
  30. Analytical evaluation of the new Beckman Coulter Access high sensitivity cardiac troponin I immunoassay
  31. Infectious Diseases
  32. Analytical evaluation of the performances of Diazyme and BRAHMS procalcitonin applied to Roche Cobas in comparison with BRAHMS PCT-sensitive Kryptor
  33. Effects of procalcitonin testing on antibiotic use and clinical outcomes in patients with upper respiratory tract infections. An individual patient data meta-analysis
  34. Acknowledgment
  35. Letters to the Editor
  36. Handling the altered test results of hemolyzed samples. Recommendations of the Quality, Management, Safety and Evidence Committee (CCGSE) of the Spanish Association of Medical Biopathology and Laboratory Medicine (AEBM-ML)
  37. Reply to: Analytical evaluation of the performances of Diazyme and BRAHMS procalcitonin applied to Roche Cobas in comparison with BRAHMS PCT-sensitive Kryptor
  38. Excessive hypercortisolemia due to ectopic Cushing’s syndrome requiring extending the reportable range for plasma cortisol for management
  39. Heavy chain disease: our experience
  40. An abnormal elevation of serum CA72-4 due to taking colchicine
  41. Rivaroxaban non-responders: do plasma measurements have a place?
  42. Next generation sequencing and immuno-histochemistry profiling identify numerous biomarkers for personalized therapy of endometrioid endometrial carcinoma
  43. A multicenter effort to improve comparability of vitamin B6 assays in whole blood
  44. PR3-anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 18.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2017-0090/html
Scroll to top button